Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment

Bortezomib, a novel proteasome inhibitor, has been approved for treating multiple myeloma and mantle cell lymphoma and studied pre-clinically and clinically for solid tumors. Preferential cytotoxicity of bortezomib was found toward hypoxic tumor cells and endothelial cells in vitro. The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiaorong, Ackerstaff, Ellen, He, Fuqiu, Xing, Ligang, Hsiao, Hung Tsung, Koutcher, Jason A., Ling, C. Clifton, Li, Gloria C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741486/
https://www.ncbi.nlm.nih.gov/pubmed/26416246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741486/
https://www.ncbi.nlm.nih.gov/pubmed/26416246

Ejemplares similares